Kura Oncology, Inc.
KURA
$9.22
-$0.52-5.34%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 71.64M | 67.48M | 104.03M | 83.28M | 67.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 71.64M | 67.48M | 104.03M | 83.28M | 67.99M |
| Cost of Revenue | 260.68M | 251.13M | 238.93M | 212.73M | 189.67M |
| Gross Profit | -189.04M | -183.65M | -134.90M | -129.45M | -121.68M |
| SG&A Expenses | 128.70M | 119.98M | 104.91M | 90.25M | 81.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 389.39M | 371.11M | 343.85M | 302.98M | 271.43M |
| Operating Income | -317.75M | -303.63M | -239.82M | -219.71M | -203.44M |
| Income Before Tax | -294.49M | -278.37M | -214.64M | -194.93M | -179.64M |
| Income Tax Expenses | 79.00K | 297.00K | 2.24M | 2.24M | 2.24M |
| Earnings from Continuing Operations | -294.57 | -278.67 | -216.88 | -197.17 | -181.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -294.57M | -278.67M | -216.88M | -197.17M | -181.89M |
| EBIT | -317.75M | -303.63M | -239.82M | -219.71M | -203.44M |
| EBITDA | -316.60M | -302.60M | -238.99M | -218.83M | -202.59M |
| EPS Basic | -3.35 | -3.18 | -2.48 | -2.26 | -2.09 |
| Normalized Basic EPS | -2.15 | -2.04 | -1.63 | -1.49 | -1.38 |
| EPS Diluted | -3.35 | -3.18 | -2.48 | -2.26 | -2.09 |
| Normalized Diluted EPS | -2.15 | -2.04 | -1.63 | -1.49 | -1.38 |
| Average Basic Shares Outstanding | 351.89M | 350.70M | 349.78M | 349.09M | 348.14M |
| Average Diluted Shares Outstanding | 351.89M | 350.70M | 349.78M | 349.09M | 348.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |